joining you you, today. Thank everyone, for us afternoon, thank and Robert. Good
As support always, Celcuity. appreciate we your continued of
to for of commercialize recently Vicky my business a on our first On gedatolisib particular comments for activities, clinical data line with licensing and this open quarter questions. collaborations. strategic other develop update discussion on gedatolisib, focusing results, our follow up trial financial we'll results call, the and then will up in with and we'll encouraging trial and clinical our Pfizer an on reported our update you agreement
develop Pfizer presented We and license a and raised worldwide $XX collaborations we We equity We trial recently. for compelling entered a inhibitor. clinical into and Pfizer data We with have had and Novartis, agreement nonclinical clinical debt. first-in-class a PIXK/mTOR signed few to exclusive approximately commercialize in gedatolisib. with And Puma. busy months million gedatolisib,
license Celcuity, transformational on from is the our a the few responsibility taking using we've Pfizer exclusive the builds clinical research for past a development years targeted step for strategic gedatolisib for the conducted Obtaining off the CELsignia platform. over therapy, of
in assessments. insights drivers unique us Our to activity live assess gives cancer ability of pathways tumor into the molecular from available proprietary cells dynamic signaling patient not
disease focus cancer, to various the mechanisms cancer to Our linked of led on pathways research us breast breast identify one complex most PIXK/mTOR. to
that dysregulated findings reveal many cancer lacking PIXK PIXK-alpha pathways mutations. breast tumors have Our despite
inhibiting Our mutations. of research of Class with I found also evidence all patients in PIXK-alpha importance isoforms PIXK the
us CELsignia to a patients cells using potentially our to ideally breast various Ultimately, generated cancer, with PIXK Pfizer the We live found in data research of findings metastatic gedatolisib's unique motivated mechanism patient and our suited in-license internal HERX-negative inhibitors and inhibit signaling. clinical tumor trial subsequently evaluated that in platform gedatolisib. ER-positive action evaluating was PIXK/mTOR-involved
to is terms licensing potential development and Pfizer cash common million stock to develop on of worldwide milestone sales. $X Celcuity Pfizer royalties additional the loaded as $XXX sales-based commercialize of Under and up upfront and exclusive granted to receive million Celcuity fee million back-end payments. and of $X also a of agreement, Celcuity's eligible an the license paid tiered receive license payments gedatolisib. to
XX XX% of endocrine with analysis cutoff data and for Ibrance January safety treatment-related and patients X trial data The or patients that Celcuity April, therapy. evaluable the majority of gedatolisib safety and benefit. XX efficacy gedatolisib inhibitor X or the found gedatolisib TRAEs of or an early most Grade had portion XXXX, Preliminary XX% an also XXX TRAEs, or the was the enrolled preliminary of and or common that that X. a evaluable an XX, expansion evaluating adverse The objective related were in clinical combination events, Grade ongoing clinical as Phase the announced XX tolerated Grade In to Ib date, in had analysis of with being the of patients also the XX found CDKX/X response, rash. X generally well Grade stomatitis
far X in This found to III the therapy and the targeted Grade target Gedatolisib Phase trial or patients study hyperglycemia all was X% had or patients only X lower isoform. hyperglycemia. X Ib trial, rate also enrolled or inhibitors Phase X that X a X Grade sharp to the in other contrast PIXK-alpha PIXK-alpha induce PIXK of cancer, for of breast where a recorded in approved Grade is in hyperglycemia. Grade alpelisib, a XX% Amongst
feedback, clinical the II/III metastatic Phase to next with and then to with first we cancer discuss in XXXX. to combination the development patients Our Subject a gedatolisib. for meet of trial endocrine gedatolisib is in with FDA’s initiate palbociclib HERX-negative FDA step ER-positive study breast an clinical would in the plans evaluating therapy our half
showed inavolisib. the signaling PIXK-alpha results inhibitor Additionally, a American PIXK/mTOR-involved evaluating Association effective in of Annual Cancer more gedatolisib, Meeting inavolisib, Xx in Research. presented inhibitor, than is with BCL of inhibition PIXK-alpha and hyperactive as patient breast navitoclax, a that with The ovarian studies tumors gedatolisib for of alone, such April, inhibitor, results we and at the a
evaluation mTOR, not and also of PIXK inhibiting and synergistic BCL isoforms patient cooperation treating of PIXK-involved results signaling all just and with between Our BCL gedatolisib potential PIXK/mTOR reveal of combining signaling tumors. detectable, was gedatolisib advantage our These further potential benefit when PIXK-alpha signaling the suggesting inhibitor. a the data showed supported internal
most development indications their in obtain therapies cellular targeted significant activity, in that that made to cases. the matching molecular treat be CELsignia a uniquely able characterize to advancing tests a is Dysregulated can targeted are tests progress This us diagnostics. patients underlying platform identify. CELsignia so help diagnostic We pathway our companies patient's CELsignia also of identifies tumor signaling, to is a opportunity prescribed. too gives dysregulated therapy the companion for signaling new our third-generation to unique complex pharmaceutical for
realizing To first the populations of step for evaluate selected represent take expands towards new activity a we a in companies the this CELsignia targeted would these step pharmaceutical to goal, targeted by their critical pathway patient efficacy test. the collaborate therapies. towards the collaborations obtaining indication evaluated that with a successful, market therapies If
believe there a patients. HERX-negative to need unmet therapeutic options for cancer significant continue We breast new for is
mechanism. and mechanism CELsignia targeted patients Our research them. suggests XX% that XX% disease many We untreated can of roughly to these the that patients most have likely to an the undiagnosed disease therapy in believe of for these benefit identify
X XXXX. results new II gaining in area Cannon a Research is Institute trial efficacy clinical expected third Xalkori, in in HERX-negative Pfizer-targeted evaluate inhibitor, begin treated Phase with half efforts the quarter, of inhibitor, Our c-Met of with a are we entered this the trial quarter this interim will And patients in collaborations. as announced, we January, of is In for into a with test. the metastatic we entered Pfizer in X trial. to previously the previously first pan-HER collaboration Sarah momentum. Vizimpro, therapies, XXXX Patient safety breast with with a our The selected enrollment and and second CELsignia cancer
trial new Novartis CELsignia cancer efficacy HERX-negative Puma and and the we targeted regimen. with MD will selected targeted agreements clinical headwinds c-Met Biotech a by second our collaboration to in are diagnosed breast Nerlynx a The advanced COVID-XX. Anderson, to hyperactive clinical with proud evaluate is and safety in patients We X these of the therapy and This trial matching In collaborations therapies. entered into from drug have now with with despite HERX study clinical Novartis' March, have and place, Tabrecta and platform. to trial collaboration treat the Puma's cancers finalized breast patients we metastatic signaling
response neoadjuvant evaluating Our identified early-stage new activity and therapies in trials our complete pathological The to goal HERX is by higher CELsignia ongoing rate a trials FACT-X FACT-X cancer to are breast that cancer patients. of patients, anti-HERX neoadjuvant treatment test test, role II recur, of we play extending than breast can standard of CELsignia demonstrate have in breast these chemotherapies. pathway HERX-negative their receive obtain to current lives complete from likely pathological drug patients treatment significant less response the care our patients. cancer believe cancer many drug anti-HERX Since who a to of a are
continue We XXXX, and early results from interim our any barring disruptions. FACT-X FACT-X to COVID-XX-related XXXX late expect trials or additional unforeseen in
world's centers. the about with opportunity of cancer research and to most some these We're prominent excited collaborations the work
have collaboration in agreements the to progress, goal quarters. We is additional in announce and coming new our discussions
and researchers, offers their our in We're test clinical thought to these investigators we to having They're their new respect believe patients. highly the leaders for oncology undiagnosed us potential to opportunity collaborate also the reflects drivers looking their will collaborating conducting be CELsignia that our respected unique with through identify the collaboration in agreements. disease forward trials interest and with
And of financings proceeds position the Vicky our initiatives. remarks. will and allow in in key Key recently $XX clinical finally, gross to closed will that us cash approximately X financing development her resulted we financing detail strengthened million. describe in fund more
results. now to our financial review to like I'd you Vicky, turn So to
